Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Thermally self-assembled biodegradable poly(casein-g-N-isopropylacrylamide) unimers and their application in drug delivery for cancer therapy.

Cuggino JC, Ambrosioni FE, Picchio ML, Nicola M, Jiménez Kairuz ÁF, Gatti G, Minari RJ, Calderón M, Alvarez Igarzabal CI, Gugliotta LM.

Int J Biol Macromol. 2020 Mar 16;154:446-455. doi: 10.1016/j.ijbiomac.2020.03.138. [Epub ahead of print]

PMID:
32194104
2.

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.

Di Federico A, Filippini DM, Dall'Olio FG, Conci N, Minari R, Tiseo M, Ardizzoni A.

Clin Cancer Res. 2020 Jan 15;26(2):518-519. doi: 10.1158/1078-0432.CCR-19-2441. No abstract available.

PMID:
31941684
3.

Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives.

Rebuzzi SE, Alfieri R, La Monica S, Minari R, Petronini PG, Tiseo M.

Crit Rev Oncol Hematol. 2020 Feb;146:102820. doi: 10.1016/j.critrevonc.2019.102820. Epub 2019 Oct 31. Review.

PMID:
31785991
4.

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M.

Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30. Review.

PMID:
31564718
5.

Controlled Thermoreversible Formation of Supramolecular Hydrogels Based on Poly(vinyl alcohol) and Natural Phenolic Compounds.

Euti EM, Wolfel A, Picchio ML, Romero MR, Martinelli M, Minari RJ, Igarzabal CIA.

Macromol Rapid Commun. 2019 Sep;40(18):e1900217. doi: 10.1002/marc.201900217. Epub 2019 Jul 10.

PMID:
31535770
6.

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.

La Monica S, Minari R, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Galetti M, Digiacomo G, Riccardi F, Petronini PG, Tiseo M, Alfieri R.

Target Oncol. 2019 Oct;14(5):619-626. doi: 10.1007/s11523-019-00669-x.

PMID:
31502118
7.

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.

La Monica S, Minari R, Cretella D, Flammini L, Fumarola C, Bonelli M, Cavazzoni A, Digiacomo G, Galetti M, Madeddu D, Falco A, Lagrasta CA, Squadrilli A, Barocelli E, Romanel A, Quaini F, Petronini PG, Tiseo M, Alfieri R.

J Exp Clin Cancer Res. 2019 May 28;38(1):222. doi: 10.1186/s13046-019-1240-x.

8.

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.

Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M.

Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19.

PMID:
31027702
9.

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.

Fumarola C, Bozza N, Castelli R, Ferlenghi F, Marseglia G, Lodola A, Bonelli M, La Monica S, Cretella D, Alfieri R, Minari R, Galetti M, Tiseo M, Ardizzoni A, Mor M, Petronini PG.

Front Oncol. 2019 Mar 26;9:179. doi: 10.3389/fonc.2019.00179. eCollection 2019.

10.

Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.

Leonetti A, Facchinetti F, Minari R, Cortellini A, Rolfo CD, Giovannetti E, Tiseo M.

Cell Oncol (Dordr). 2019 Jun;42(3):261-273. doi: 10.1007/s13402-019-00441-3. Epub 2019 Apr 9. Review.

PMID:
30968324
11.

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.

Del Re M, Bordi P, Rofi E, Restante G, Valleggi S, Minari R, Crucitta S, Arrigoni E, Chella A, Morganti R, Tiseo M, Petrini I, Danesi R.

Br J Cancer. 2018 Nov;119(10):1252-1258. doi: 10.1038/s41416-018-0238-z. Epub 2018 Nov 6.

12.

Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in EGFR-mutated non-small cell lung cancer.

Facchinetti F, Bozzetti F, Minari R, Ceccon G, Zielli T, Florindo I, Crisi G, Tiseo M.

Tumori. 2018 Dec;104(6):NP29-NP33. doi: 10.1177/0300891618809826. Epub 2018 Nov 5.

PMID:
30392443
13.

Effect of Delivery Platforms Structure on the Epidermal Antigen Transport for Topical Vaccination.

Sonzogni AS, Yealland G, Kar M, Wedepohl S, Gugliotta LM, Gonzalez VDG, Hedtrich S, Calderón M, Minari RJ.

Biomacromolecules. 2018 Dec 10;19(12):4607-4616. doi: 10.1021/acs.biomac.8b01307. Epub 2018 Nov 14.

PMID:
30376297
14.

L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib.

Callegari D, Ranaghan KE, Woods CJ, Minari R, Tiseo M, Mor M, Mulholland AJ, Lodola A.

Chem Sci. 2018 Feb 12;9(10):2740-2749. doi: 10.1039/c7sc04761d. eCollection 2018 Mar 14.

15.

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, Tiseo M, Planchard D.

Cancer Treat Rev. 2018 May;66:82-94. doi: 10.1016/j.ctrv.2018.04.006. Epub 2018 Apr 24. Review.

PMID:
29729495
16.

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

Minari R, Bordi P, La Monica S, Squadrilli A, Leonetti A, Bottarelli L, Azzoni C, Lagrasta CAM, Gnetti L, Campanini N, Petronini PG, Alfieri R, Tiseo M.

J Thorac Oncol. 2018 Jun;13(6):e89-e91. doi: 10.1016/j.jtho.2018.03.013. Epub 2018 Mar 27. No abstract available.

17.

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C, Nizzoli R, Bortesi B, Rofi E, Petreni P, Campanini N, Rossi G, Danesi R, Tiseo M.

Lung Cancer. 2018 Jan;115:21-27. doi: 10.1016/j.lungcan.2017.11.011. Epub 2017 Nov 13.

PMID:
29290257
18.

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.

La Monica S, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Digiacomo G, Flammini L, Barocelli E, Minari R, Naldi N, Petronini PG, Tiseo M, Alfieri R.

J Exp Clin Cancer Res. 2017 Dec 4;36(1):174. doi: 10.1186/s13046-017-0653-7.

19.

Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.

Proto C, Lo Russo G, Corrao G, Ganzinelli M, Facchinetti F, Minari R, Tiseo M, Garassino MC.

Tumori. 2017 Jul 31;103(4):325-337. doi: 10.5301/tj.5000663. Epub 2017 Jul 1. Review.

PMID:
28708233
20.

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.

Facchinetti F, Rossi G, Bria E, Soria JC, Besse B, Minari R, Friboulet L, Tiseo M.

Cancer Treat Rev. 2017 Apr;55:83-95. doi: 10.1016/j.ctrv.2017.02.010. Epub 2017 Mar 12. Review.

PMID:
28342334
21.

Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.

Facchinetti F, Proto C, Minari R, Garassino M, Tiseo M.

Handb Exp Pharmacol. 2018;249:63-89. doi: 10.1007/164_2017_16.

PMID:
28332047
22.
23.

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

Bersanelli M, Minari R, Bordi P, Gnetti L, Bozzetti C, Squadrilli A, Lagrasta CA, Bottarelli L, Osipova G, Capelletto E, Mor M, Tiseo M.

J Thorac Oncol. 2016 Oct;11(10):e121-3. doi: 10.1016/j.jtho.2016.05.019. Epub 2016 May 31. No abstract available.

24.

A new variant in signal peptide of the human luteinizing hormone receptor (LHCGR) affects receptor biogenesis causing leydig cell hypoplasia.

Vezzoli V, Duminuco P, Vottero A, Kleinau G, Schülein R, Minari R, Bassi I, Bernasconi S, Persani L, Bonomi M.

Hum Mol Genet. 2015 Nov 1;24(21):6003-12. doi: 10.1093/hmg/ddv313. Epub 2015 Aug 5.

25.

A novel mutation in the NR0B1 gene in a family with monozygotic twin sisters and congenital adrenal hypoplasia affected children.

Minari R, Vottero A, Tassi F, Viani I, Neri TM, Street ME, Ghizzoni L, Bernasconi S, Martorana D.

Hormones (Athens). 2015 Jan-Mar;14(1):160-6. doi: 10.14310/horm.2002.1490.

26.

High-intensity focused ultrasound for prostate cancer: long-term followup and complications rate.

Maestroni U, Dinale F, Minari R, Salsi P, Ziglioli F.

Adv Urol. 2012;2012:960835. doi: 10.1155/2012/960835. Epub 2012 Aug 15.

27.

Evidence for epigenetic abnormalities of the androgen receptor gene in foreskin from children with hypospadias.

Vottero A, Minari R, Viani I, Tassi F, Bonatti F, Neri TM, Bertolini L, Bernasconi S, Ghizzoni L.

J Clin Endocrinol Metab. 2011 Dec;96(12):E1953-62. doi: 10.1210/jc.2011-0511. Epub 2011 Sep 21.

28.

Latex imaging by environmental STEM: application to the study of the surfactant outcome in hybrid alkyd/acrylate systems.

Faucheu J, Chazeau L, Gauthier C, Cavaillé JY, Goikoetxea M, Minari R, Asua JM.

Langmuir. 2009 Sep 1;25(17):10251-8. doi: 10.1021/la901049h.

PMID:
19537700
29.

Attitudes to, and practice of, unconventional medicine by physicians in Italy.

Cocconi G, Caminiti C, Capriglia S, Gennari M, Minari R, Schianchi P, d'Aloia T.

Eur J Intern Med. 2006 Jan;17(1):32-7.

PMID:
16378883
30.

[Renal lymphoma: an atypical mass in search of characterization].

Barbieri A, Monica B, Minari R, Melissari M, Salsi P.

Arch Ital Urol Androl. 1997 Jun;69(3):155-8. Italian.

PMID:
9273089
31.

[Small-cell carcinoma of the bladder: description of a case and review of the literature].

Minari R, Monica B, Ricci R, Puviani PP, Franzini M.

Arch Ital Urol Androl. 1994 Feb;66(1):57-60. Review. Italian.

PMID:
8012427

Supplemental Content

Loading ...
Support Center